pazopanib

Overview

Pazopanib is an FDA-approved multi-target tyrosine kinase inhibitor targeting VEGFR1/2/3, PDGFRA/B, and KIT. It has regulatory approval for advanced soft-tissue sarcoma (excluding liposarcoma) after prior chemotherapy.

Evidence in the corpus

• RMS PDTOs from the UCLA functional sarcoma screen were significantly more sensitive than the pan-sarcoma average to pazopanib (p=0.049). PMID:39305899
• Specimens from patients who had received ≥3 prior therapy lines showed a trend toward enhanced sensitivity to pazopanib (p=0.0062), consistent with a late-line activity profile in heavily pre-treated sarcomas. PMID:39305899
• High PIK3R2 and FGFR3 expression guided pazopanib recommendation in metastatic NEN patients (PN1, PN14, PN17, PN25) in the POG NEN WGTA cohort PMID:24326773
• Nominated for Triple-WT melanoma subtype (14% of 318 TCGA cases) to target co-amplified PDGFRA/KDR at 4q12 alongside imatinib, dasatinib, sorafenib, crenolanib, and regorafenib PMID:26091043

Resistance mechanisms

• Not reported in corpus.

Cancer types (linked)

• RMS

Sources

• PMID:39305899 — Duminuco et al. 2024, UCLA PDTO sarcoma functional screen; RMS subtype sensitivity and pre-treatment history associations.

This page was processed by crosslinker on 2026-05-14. - PMID:24326773

This page was processed by crosslinker on 2026-05-14. - PMID:26091043

This page was processed by crosslinker on 2026-05-14.